

Administration**PATIENT GROUP DIRECTION (PGD) FOR****LIDOCAINE (LIGNOCAINE) 1% INJECTION**

YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

Clinical Condition	
Indication	For local anaesthesia
Inclusion criteria	Patients presenting at MIU or individuals in custodial institutions requiring surface analgesia due to wound management procedures or removal of a foreign body OR requiring digit ring block.
Exclusion criteria If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber	<ul style="list-style-type: none"> Previous allergic reactions to local anaesthetics Individuals with porphyria Hypovolaemia (e.g. through fluid loss) Known impaired cardiac conduction, heart block Bradycardia (Pulse rate less than 60 beats per minute) Epilepsy, myasthenia gravis, heart failure Impaired renal or hepatic function Interacting drugs Use in the eye
Cautions - Seek further advice from doctor before proceeding and document advice	Third trimester of pregnancy
Further information	<p>Dose used must take into account the patient's age, weight, physique, clinical condition, the degree of vascularity of the area involved and the duration of the administration.</p> <p>Great care must be taken to avoid accidental intra-venous injection</p> <p>Maximum arterial plasma concentrations occur within 10-25 minutes therefore patients should be observed for 30 minutes following injection.</p> <p>Check for onset of adequate anaesthesia before commencing procedure.</p> <p>The effect of local anaesthetics may be reduced if the injection is made into an inflamed or infected area</p>
Action if patient declines or is excluded	Refer to doctor, A & E as appropriate




Administration**PATIENT GROUP DIRECTION (PGD) FOR****LIDOCAINE (LIGNOCAINE) 1% INJECTION**

Drug Details	
Name, form & strength of medicine	Lidocaine hydrochloride 1% injection 2ml (20mg)
Legal status	Prescription Only Medicine (POM)
Route/Method	Local tissue infiltration / ring block
Dosage	As required to maintain local anaesthesia Single doses of Lidocaine should not exceed 4.5 mg/kg (or 200 mg total dose) in adults or children 12 – 18 years of age Lidocaine by local infiltration for children under the age of 12 years should not exceed 3 mg/kg,
Frequency	As needed to maintain anaesthesia
Quantity to administer	Repeated not more often than every 4 hours.
Side effects	Rarely confusion, respiratory depression, convulsions, bradycardia.
Advice to patient/carer	Full anaesthesia may remain for up to 90 minutes. Normal sensation may take several hours to return fully. Do not drive or operate machinery until fully recovered.
Follow up	Advise as appropriate

Administration

PATIENT GROUP DIRECTION (PGD) FOR

LIDOCAINE (LIGNOCAINE) 1% INJECTION

Staff Characteristics	
Professional qualifications	Nurses on the NMC Register
Specialist competencies or qualifications	A registered nurse, after discussion and agreement with the MIU service/departmental lead. Has undertaken appropriate training for working under PGDs for the supply and administration of medicines.
Continuing education & training	The practitioner should be aware of any change to the recommendations for the medicine listed. It is the responsibility of the individual to keep up-to-date with clinical developments as part of their continued professional development.
Referral Arrangements and Audit Trail	
Records/audit trail	Patient's name, address, date of birth. Contact details of GP (if registered). Diagnosis. Advice given to patient (including side effects). Signature/name of staff who administered the medication. Details of any adverse drug reaction and actions taken including documentation in the patient's medical record Referral arrangements (including self-care) Record the use of the PGD in the departmental log.
References/Resources and comments	SPC – Summary of Product Characteristics BNF – British National Formulary
Clinical Authorisation	
Lead Doctor	Dr Andrew Sant, Medical Director Signature:  Date: 12/10/17
Lead Pharmacist	Dr Alex Johnson, Prescribing Support Pharmacist Signature:  Date: 11 Oct 17
Organisational Authorisation	
On behalf of Worcestershire Health and Care NHS Trust	Michelle Clarke, Director of Nursing & Quality Signature:  Date: 12/10/17
Patient Group Direction Peer Reviewed by	
Senior MIU Nurses	

